X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (75) 75
hematology (33) 33
male (32) 32
myelodysplastic syndromes (32) 32
index medicus (31) 31
oncology (31) 31
female (29) 29
aged (23) 23
middle aged (23) 23
myelodysplastic syndromes - drug therapy (21) 21
myelodysplastic syndromes - genetics (21) 21
animals (19) 19
aged, 80 and over (18) 18
myelodysplastic syndromes - pathology (17) 17
apoptosis (15) 15
base sequence (14) 14
molecular sequence data (14) 14
mice (13) 13
acute myeloid-leukemia (12) 12
research (12) 12
cancer (11) 11
prognosis (11) 11
bone marrow (10) 10
care and treatment (10) 10
mutation (10) 10
risk factors (10) 10
adult (9) 9
chromosome deletion (9) 9
expression (9) 9
thalidomide - therapeutic use (9) 9
article (8) 8
child (8) 8
health aspects (8) 8
hemic and lymphatic diseases (8) 8
karyotyping (8) 8
lenalidomide (8) 8
leukemia (8) 8
myelodysplastic syndrome (8) 8
abridged index medicus (7) 7
anemia (7) 7
bone marrow - pathology (7) 7
cell line (7) 7
cells, cultured (7) 7
hematology, oncology and palliative medicine (7) 7
myelodysplastic syndromes - mortality (7) 7
polymerase chain reaction (7) 7
proliferation (7) 7
survival analysis (7) 7
thalidomide (7) 7
thalidomide - analogs & derivatives (7) 7
amino acid sequence (6) 6
antineoplastic agents - therapeutic use (6) 6
cancer research (6) 6
cells (6) 6
chromosomes, human, pair 5 - genetics (6) 6
cloning, molecular (6) 6
dna (6) 6
dna-binding proteins - genetics (6) 6
gene (6) 6
genetics & heredity (6) 6
glutathione - analogs & derivatives (6) 6
identification (6) 6
ribosomes - genetics (6) 6
survival (6) 6
transcription factors (6) 6
translocation, genetic (6) 6
adolescent (5) 5
azacitidine - analogs & derivatives (5) 5
azacitidine - therapeutic use (5) 5
bone marrow cells - pathology (5) 5
cell differentiation (5) 5
child, preschool (5) 5
chromosome mapping (5) 5
classification (5) 5
cytogenetics (5) 5
diagnosis (5) 5
digeorge syndrome - genetics (5) 5
diseases of the blood and blood-forming organs (5) 5
dna - genetics (5) 5
dna mutational analysis (5) 5
gene rearrangement (5) 5
genetic aspects (5) 5
immunoglobulin heavy chains - genetics (5) 5
molecular biology (5) 5
patient outcomes (5) 5
phenotype (5) 5
predictive value of tests (5) 5
remission induction (5) 5
treatment outcome (5) 5
acute myeloid leukemia (4) 4
antibody formation (4) 4
b-lymphocytes - immunology (4) 4
cell division (4) 4
cell lineage (4) 4
chromosome aberrations (4) 4
cytogenetic analysis (4) 4
diseases (4) 4
dna, neoplasm - genetics (4) 4
dose-response relationship, drug (4) 4
erythropoiesis (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 26, pp. 2496 - 2506
Journal Article
Nature, ISSN 0028-0836, 01/2008, Volume 451, Issue 7176, pp. 335 - 339
Somatic chromosomal deletions in cancer are thought to indicate the location of tumour suppressor genes, by which a complete loss of gene function occurs... 
DIAMOND-BLACKFAN ANEMIA | MYELOID DISORDERS | EXPRESSION | CANCER | MULTIDISCIPLINARY SCIENCES | CHROMOSOME 5Q DELETION | Ribosomal proteins | Genetic aspects | Research | Diagnosis | Health aspects | Myelodysplastic syndromes | Risk factors | Genotype & phenotype | Ribonucleic acid | Genetics | Mutation | Ribonucleic acid--RNA | Chromosomes | Cancer
Journal Article
Journal Article
Nature: international weekly journal of science, ISSN 0028-0836, 01/2014, Volume 506, Issue 7487, pp. 240 - 244
textabstractCells of the osteoblast lineage affect the homing and the number of long-term repopulating haematopoietic stem cells, haematopoietic stem cell... 
PROGENITOR CELLS | MULTIDISCIPLINARY SCIENCES | ACUTE LYMPHOBLASTIC-LEUKEMIA | BONE-MARROW NICHE | NOTCH ACTIVATION | STEM-CELL NICHE | MYELOID-LEUKEMIA | MICE | DIFFERENTIATION | EXPRESSION | MYELODYSPLASTIC SYNDROMES | Osteoblasts - secretion | Receptors, Notch - metabolism | Humans | Leukemia, Myeloid, Acute - metabolism | Hematopoietic Stem Cells - pathology | Anemia - pathology | Male | Cell Differentiation - genetics | Intercellular Signaling Peptides and Proteins - metabolism | Membrane Proteins - deficiency | Anemia - genetics | Cell Nucleus - metabolism | Tumor Microenvironment - genetics | Cell Transformation, Neoplastic - genetics | Serrate-Jagged Proteins | Base Sequence | Female | Membrane Proteins - metabolism | Intercellular Signaling Peptides and Proteins - deficiency | Jagged-1 Protein | Calcium-Binding Proteins - metabolism | Myelodysplastic Syndromes - metabolism | Signal Transduction | Leukemia, Myeloid, Acute - pathology | Membrane Proteins - genetics | Intercellular Signaling Peptides and Proteins - genetics | Calcium-Binding Proteins - deficiency | Hematopoietic Stem Cells - metabolism | Mutation - genetics | beta Catenin - metabolism | beta Catenin - genetics | Anemia - metabolism | Cell Lineage | Osteoblasts - pathology | Animals | Chromosome Aberrations | Myeloid Cells - metabolism | Ligands | Mice | Myelodysplastic Syndromes - genetics | Myeloid Cells - pathology | Cell Transformation, Neoplastic - pathology | Myelodysplastic Syndromes - pathology | Osteoblasts - metabolism | Calcium-Binding Proteins - genetics | Leukemia, Myeloid, Acute - genetics
Journal Article
PLoS Medicine, ISSN 1549-1277, 02/2008, Volume 5, Issue 2, pp. 0312 - 0322
Background Lenalidomide is an effective new agent for the treatment of patients with myelodysplastic syndrome (MDS), an acquired hematopoietic disorder... 
APOPTOSIS | MEDICINE, GENERAL & INTERNAL | COMMONLY DELETED REGION | DISEASES | SET ENRICHMENT ANALYSIS | CLASSIFICATION | PROLIFERATION | THALIDOMIDE | CHROMOSOME-5 | TISSUES | DISCOVERY | Predictive Value of Tests | Erythroid Precursor Cells - drug effects | Humans | Middle Aged | Erythropoiesis - drug effects | Male | Myelodysplastic Syndromes - blood | Thalidomide - pharmacology | Erythroid Precursor Cells - physiology | Cell Differentiation - genetics | Thalidomide - analogs & derivatives | Aged, 80 and over | Hematopoietic Stem Cells - physiology | Adult | Chromosomes, Human, Pair 5 - drug effects | Myelodysplastic Syndromes - drug therapy | Chromosomes, Human, Pair 5 - genetics | Erythropoiesis - genetics | Chromosome Deletion | Hematopoietic Stem Cells - drug effects | Cells, Cultured | Gene Expression Profiling - methods | Genetic Markers - drug effects | Cell Differentiation - drug effects | Genetic Markers - genetics | Aged | Myelodysplastic Syndromes - genetics | Clinical Trials, Phase II as Topic - methods | Thalidomide - therapeutic use | Index Medicus | Genetics and Genomics | Oncology | Chemotherapy | Hematology (including Blood Transfusion) | Hematology | Medical research | Transplants & implants | Cytokines | Leukemia | Colonies & territories | Gene expression | Experiments | Cancer therapies | Blood clots | Defects | Studies | Confidence intervals | Bone marrow | Chromosomes | Drug dosages | Cancer
Journal Article
Journal Article
Journal Article
Expert Opinion on Investigational Drugs, ISSN 1354-3784, 07/2006, Volume 15, Issue 7, pp. 805 - 813
This review summarises the mechanism of action of immunomodulatory analogues of thalidomide and their use in myelodysplastic syndromes. Thalidomide was found... 
lenalidomide | thalidomide | del(5q) | IMiDs | myelodysplastic syndromes | SelCIDs | iMiDs | Lenalidomide | Thalidomide | Del(5q) | Myelodysplastic syndromes | Apoptosis - drug effects | Humans | Middle Aged | Drugs, Investigational - therapeutic use | Erythropoiesis - drug effects | Male | Thalidomide - pharmacology | Cytokines - physiology | Thalidomide - analogs & derivatives | Myelodysplastic Syndromes - therapy | Blood Transfusion | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Drug Evaluation, Preclinical | Neutropenia - chemically induced | Angiogenesis Inhibitors - adverse effects | Myelodysplastic Syndromes - drug therapy | Chromosome Deletion | Hematopoietic Stem Cells - drug effects | Thalidomide - adverse effects | Cells, Cultured - drug effects | NF-kappa B - antagonists & inhibitors | Erythrocyte Transfusion | Thalidomide - chemistry | Angiogenesis Inhibitors - pharmacology | Clinical Trials as Topic | Thrombocytopenia - chemically induced | Chromosomes, Human, Pair 5 - ultrastructure | Cell Lineage | Pilot Projects | Animals | Tumor Necrosis Factor-alpha - physiology | Aged | Immunologic Factors - adverse effects | Myelodysplastic Syndromes - genetics | Thalidomide - therapeutic use | Immunologic Factors - pharmacology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Immunologic Factors - therapeutic use
Journal Article
Blood, ISSN 0006-4971, 10/2014, Volume 124, Issue 18, pp. 2834 - 2846
Journal Article
Blood, ISSN 0006-4971, 11/2011, Volume 118, Issue 21, pp. 5031 - 5031
Abstract Abstract 5031 Purpose Myelodysplastic syndromes (MDS) are typically characterized by peripheral blood cytopenias. However, some MDS is associated with... 
Journal Article